HealthyNCT06901362
Seroprevalence and Vaccination Rate of Hepatitis B Virus and Varicella-zoster Virus Among Medical Students Under Immunizing Program
An observational study of Healthy and Healthy Adult, run by Thammasat University at 1 site in Thailand.
Trial summary
This study is a cross-sectional study. The study aims to determine the levels of immunity against hepatitis B virus and varicella-zoster virus in medical students. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Healthy, Healthy Adult
- How many people
- 401 participants
- Where
- 1 siteThailand
- Study dates
- 1 Apr 2025to 30 Nov 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Medical students aged 18 years or older are included.
Who may be able to join
- Medical students
- Age 18 years or older
Who cannot join
- Known cases of hepatitis B virus infection
- Known cases of varicella-zoster virus infection
Trial locations and contacts
1 site in 1 country.
Thailand1 site
Narongkorn Saiphoklang
Pathum Thani, Changwat Pathum Thani, 12120
About this study
This study is a cross-sectional study. The study aims to determine the levels of immunity against hepatitis B virus and varicella-zoster virus in medical students.
Read the detailed description
This study is a cross-sectional study aimed at determining the levels of immunity against the hepatitis B virus and varicella virus in medical students. Additionally, it aims to compare the rate of increase in immunity levels before and after receiving the hepatitis B and varicella-zoster vaccines in medical students. Medical students aged 18 years or older are included in the study.
- Conditions
- Healthy, Healthy Adult
- Keywords
- hepatitis B virus, varicella-zoster virus, vaccination, immunizing program, medical students
- Medical subject headings
- Hepatitis B, Chickenpox
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Medical students | Medical students aged 18 years or older |
What is being measured
The primary outcome is the main question the study is designed to answer.
The seroprevalence of hepatitis B virus
The immunity level against the hepatitis B virus is assessed.
Measured: From enrollment to the end of treatment at 6 months
The seroprevalence of varicella-zoster virus
The immunity level against varicella-zoster virus is assessed.
Measured: From enrollment to the end of treatment at 6 months
Secondary outcomes (2)
The vaccination rate of hepatitis B virus
The vaccination rate of hepatitis B virus is assessed.
Measured: From enrollment to the end of treatment at 6 months
The vaccination rate of varicella-zoster virus
The vaccination rate of varicella-zoster virus is assessed.
Measured: From enrollment to the end of treatment at 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Mar 2025
- Study start1 Apr 2025
- Primary completion31 Aug 2025
- Study completion30 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (12)Papers the sponsor has linked to this study.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 401 participants (actual)
Sponsor and investigators
- Lead sponsor
- Thammasat University
- Sponsor type
- University, hospital or other
- Collaborators
- Thammasat University Hospital
- Responsible party
- Principal investigator, Narongkorn Saiphoklang, MD, Thammasat University
- Investigators
- Narongkorn Saiphoklang, MD, Principal investigator, Thammasat University Faculty of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06901362
- Sponsor's protocol ID
- MTU-EC-SA-0-159/67
- Status last verified
- Apr 2025
- First submitted
- 22 Mar 2025
- Last updated
- 23 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD and documents will be available for sharing immediately after publication for a period of 2 years.
Publications
Techasathit W, Ratanasuwan W, Sonjai A, Sangsiriwut K, Anekthananon T, Suwanagool S. Vaccination against hepatitis B virus: are Thai medical students sufficiently protected? J Med Assoc Thai. 2005 Mar;88(3):329-34.
PubMed 15962639Baer G, Bonhoeffer J, Schaad UB, Heininger U. Seroprevalence and immunization history of selected vaccine preventable diseases in medical students. Vaccine. 2005 Mar 14;23(16):2016-20. doi: 10.1016/j.vaccine.2004.03.073.
PubMed 15734076Balbi O, Baldi S, Rizza S, Pietroiusti A, Perrone S, Coppeta L. Seroprevalence survey for Varicella among healthcare workers and medical students in Italy. Hum Vaccin Immunother. 2021 Feb 1;17(2):372-376. doi: 10.1080/21645515.2020.1771989. Epub 2020 Jul 9.
PubMed 32643520Pourakbari B, Shahbaznezhad L, Parvaneh N, Nikkhah S, Mahmoudi S, Teymuri M, Alyari A, Mamishi S. Seroepidemiology of Varicella Zoster Virus among children, adolescents and medical students in a referral children medical center, Tehran, Iran. Iran J Microbiol. 2012 Sep;4(3):136-8.
PubMed 23066488Sheek-Hussein M, Hashmey R, Alsuwaidi AR, Al Maskari F, Amiri L, Souid AK. Seroprevalence of measles, mumps, rubella, varicella-zoster and hepatitis A-C in Emirati medical students. BMC Public Health. 2012 Dec 5;12:1047. doi: 10.1186/1471-2458-12-1047.
PubMed 23217121Cardenas-Perea ME, Gomez-Conde E, Santos-Lopez G, Perez-Contreras I, Diaz-Orea MA, Gandara-Ramirez JL, Cruz Y Lopez OR, Marquez-Dominguez L, Sosa-Jurado F. Hepatitis B surface antibodies in medical students from a public university in Puebla, Mexico. Hum Vaccin Immunother. 2016 Jul 2;12(7):1857-62. doi: 10.1080/21645515.2016.1151587. Epub 2016 May 12.
PubMed 27171749Sartorelli P, Occhialini F, Miceli R, Pietronigro A, Bianciardi L, Salini C, Messina G. The seroprevalence of the hepatitis B virus in Italian medical students after 3 decades since the introduction of universal vaccination. Int J Occup Med Environ Health. 2022 Feb 15;35(1):75-80. doi: 10.13075/ijomeh.1896.01835. Epub 2021 Aug 25.
PubMed 34448470Tesfa T, Hawulte B, Tolera A, Abate D. Hepatitis B virus infection and associated risk factors among medical students in eastern Ethiopia. PLoS One. 2021 Feb 19;16(2):e0247267. doi: 10.1371/journal.pone.0247267. eCollection 2021.
PubMed 33606777Rathi A, Kumar V, Majhi J, Jain S, Lal P, Singh S. Assessment of knowledge, attitude, and practices toward prevention of hepatitis B infection among medical students in a high-risk setting of a newly established medical institution. J Lab Physicians. 2018 Oct-Dec;10(4):374-379. doi: 10.4103/JLP.JLP_93_18.
PubMed 30498306Yoda T, Katsuyama H. Analysis of antibody-negative medical students after hepatitis B vaccination in Japan. Hum Vaccin Immunother. 2021 Mar 4;17(3):852-856. doi: 10.1080/21645515.2020.1788309. Epub 2020 Aug 5.
PubMed 32755433Bianchi FP, Tafuri S, Larocca AMV, Germinario CA, Stefanizzi P. Long -term persistence of antibodies against varicella in fully immunized healthcare workers: an Italian retrospective cohort study. BMC Infect Dis. 2021 May 25;21(1):475. doi: 10.1186/s12879-021-06180-x.
PubMed 34034659Phattraprayoon N, Kakheaw J, Soonklang K, Cheirsilpa K, Ungtrakul T, Auewarakul C, Mahanonda N. Duration of Hepatitis B Vaccine-Induced Protection among Medical Students and Healthcare Workers following Primary Vaccination in Infancy and Rate of Immunity Decline. Vaccines (Basel). 2022 Feb 10;10(2):267. doi: 10.3390/vaccines10020267.
PubMed 35214725
Study at a glance
From the registry record, last updated by the sponsor on 23 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Seroprevalence and Vaccination Rate of Hepatitis B Virus and Varicella-zoster Virus Among Medical Students Under Immunizing Program
- ClinicalTrials.gov ID
- NCT06901362
- Acronym / sponsor ID
- MTU-EC-SA-0-159/67
- Conditions
- Healthy, Healthy Adult
- Keywords
- hepatitis B virus, varicella-zoster virus, vaccination, immunizing program, medical students
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 401 participants (actual)
- Lead sponsor
- Thammasat UniversityUniversity, hospital or other
- Collaborators
- Thammasat University Hospital
- Study start
- 1 Apr 2025 (actual)
- Primary completion
- 31 Aug 2025 (actual)
- Study completion
- 30 Nov 2025 (actual)
- First posted
- 28 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a cross-sectional study. The study aims to determine the levels of immunity against hepatitis B virus and varicella-zoster virus in medical students.
Detailed description
This study is a cross-sectional study aimed at determining the levels of immunity against the hepatitis B virus and varicella virus in medical students. Additionally, it aims to compare the rate of increase in immunity levels before and after receiving the hepatitis B and varicella-zoster vaccines in medical students. Medical students aged 18 years or older are included in the study.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Medical students | – | –Medical students aged 18 years or older |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Medical students aged 18 years or older are included.
Key inclusion criteria (2 listed)
- Medical students
- Age 18 years or older
Key exclusion criteria (2 listed)
- Known cases of hepatitis B virus infection
- Known cases of varicella-zoster virus infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The seroprevalence of hepatitis B virus
Time frame: From enrollment to the end of treatment at 6 months
The immunity level against the hepatitis B virus is assessed.
The seroprevalence of varicella-zoster virus
Time frame: From enrollment to the end of treatment at 6 months
The immunity level against varicella-zoster virus is assessed.
2 secondary outcomes
The vaccination rate of hepatitis B virus
Time frame: From enrollment to the end of treatment at 6 months
The vaccination rate of varicella-zoster virus
Time frame: From enrollment to the end of treatment at 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Dec 2025.
- Results publication: PubMed 15962639Techasathit W, Ratanasuwan W, Sonjai A, Sangsiriwut K, Anekthananon T, Suwanagool S. Vaccination against hepatitis B virus: are Thai medical students sufficiently protected? J Med Assoc Thai. 2005 Mar;88(3):329-34.
- Results publication: PubMed 15734076Baer G, Bonhoeffer J, Schaad UB, Heininger U. Seroprevalence and immunization history of selected vaccine preventable diseases in medical students. Vaccine. 2005 Mar 14;23(16):2016-20. doi: 10.1016/j.vaccine.2004.03.073.
- Results publication: PubMed 32643520Balbi O, Baldi S, Rizza S, Pietroiusti A, Perrone S, Coppeta L. Seroprevalence survey for Varicella among healthcare workers and medical students in Italy. Hum Vaccin Immunother. 2021 Feb 1;17(2):372-376. doi: 10.1080/21645515.2020.1771989. Epub 2020 Jul 9.
- Results publication: PubMed 23066488Pourakbari B, Shahbaznezhad L, Parvaneh N, Nikkhah S, Mahmoudi S, Teymuri M, Alyari A, Mamishi S. Seroepidemiology of Varicella Zoster Virus among children, adolescents and medical students in a referral children medical center, Tehran, Iran. Iran J Microbiol. 2012 Sep;4(3):136-8.
- Results publication: PubMed 23217121Sheek-Hussein M, Hashmey R, Alsuwaidi AR, Al Maskari F, Amiri L, Souid AK. Seroprevalence of measles, mumps, rubella, varicella-zoster and hepatitis A-C in Emirati medical students. BMC Public Health. 2012 Dec 5;12:1047. doi: 10.1186/1471-2458-12-1047.
- Results publication: PubMed 27171749Cardenas-Perea ME, Gomez-Conde E, Santos-Lopez G, Perez-Contreras I, Diaz-Orea MA, Gandara-Ramirez JL, Cruz Y Lopez OR, Marquez-Dominguez L, Sosa-Jurado F. Hepatitis B surface antibodies in medical students from a public university in Puebla, Mexico. Hum Vaccin Immunother. 2016 Jul 2;12(7):1857-62. doi: 10.1080/21645515.2016.1151587. Epub 2016 May 12.
- Results publication: PubMed 34448470Sartorelli P, Occhialini F, Miceli R, Pietronigro A, Bianciardi L, Salini C, Messina G. The seroprevalence of the hepatitis B virus in Italian medical students after 3 decades since the introduction of universal vaccination. Int J Occup Med Environ Health. 2022 Feb 15;35(1):75-80. doi: 10.13075/ijomeh.1896.01835. Epub 2021 Aug 25.
- Results publication: PubMed 33606777Tesfa T, Hawulte B, Tolera A, Abate D. Hepatitis B virus infection and associated risk factors among medical students in eastern Ethiopia. PLoS One. 2021 Feb 19;16(2):e0247267. doi: 10.1371/journal.pone.0247267. eCollection 2021.
- Results publication: PubMed 30498306Rathi A, Kumar V, Majhi J, Jain S, Lal P, Singh S. Assessment of knowledge, attitude, and practices toward prevention of hepatitis B infection among medical students in a high-risk setting of a newly established medical institution. J Lab Physicians. 2018 Oct-Dec;10(4):374-379. doi: 10.4103/JLP.JLP_93_18.
- Results publication: PubMed 32755433Yoda T, Katsuyama H. Analysis of antibody-negative medical students after hepatitis B vaccination in Japan. Hum Vaccin Immunother. 2021 Mar 4;17(3):852-856. doi: 10.1080/21645515.2020.1788309. Epub 2020 Aug 5.
- Results publication: PubMed 34034659Bianchi FP, Tafuri S, Larocca AMV, Germinario CA, Stefanizzi P. Long -term persistence of antibodies against varicella in fully immunized healthcare workers: an Italian retrospective cohort study. BMC Infect Dis. 2021 May 25;21(1):475. doi: 10.1186/s12879-021-06180-x.
- Results publication: PubMed 35214725Phattraprayoon N, Kakheaw J, Soonklang K, Cheirsilpa K, Ungtrakul T, Auewarakul C, Mahanonda N. Duration of Hepatitis B Vaccine-Induced Protection among Medical Students and Healthcare Workers following Primary Vaccination in Infancy and Rate of Immunity Decline. Vaccines (Basel). 2022 Feb 10;10(2):267. doi: 10.3390/vaccines10020267.
- Individual participant dataSharing planned: Yes. IPD and documents will be available for sharing immediately after publication for a period of 2 years.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Narongkorn Saiphoklang, MD principal investigator
Thammasat University Faculty of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Healthy and Healthy Adult, run by Thammasat University at 1 site in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The seroprevalence of hepatitis B virus (time frame: From enrollment to the end of treatment at 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06901362, which also lists 12 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Dec 2025.